Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 90.1% in April

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 69,800 shares, a decline of 90.1% from the March 31st total of 706,700 shares. Based on an average daily volume of 881,000 shares, the short-interest ratio is currently 0.1 days. Approximately 7.3% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sunshine Biopharma stock. Armistice Capital LLC grew its holdings in Sunshine Biopharma, Inc. (NASDAQ:SBFM) by 118.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,130,000 shares of the company’s stock after acquiring an additional 1,156,000 shares during the period. Armistice Capital LLC owned about 8.29% of Sunshine Biopharma worth $578,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 41.98% of the company’s stock.

Sunshine Biopharma Stock Down 13.2 %

SBFM traded down $0.12 during midday trading on Thursday, reaching $0.81. The company had a trading volume of 13,931,183 shares, compared to its average volume of 897,672. Sunshine Biopharma has a 1 year low of $0.75 and a 1 year high of $140.00. The company has a market cap of $799,326.00, a P/E ratio of -0.04 and a beta of 1.17. The business has a 50-day moving average of $6.13 and a two-hundred day moving average of $19.36.

Sunshine Biopharma (NASDAQ:SBFM) last released its earnings results on Thursday, March 28th. The company reported ($5.00) EPS for the quarter. The firm had revenue of $7.68 million for the quarter. Sunshine Biopharma had a negative return on equity of 21.03% and a negative net margin of 18.70%.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents.